2Frei E 3rd. Clinical cancer research:an embattled species [ J 1. Cancer, 1982,50(10) :1979 - 1992. 被引量：1
3Kurosumi M. Significance and problems in evaluations of pathologi- cal responses to neoadjuvant therapy for breast cancer [ J ]. Breast Cancer,2006,13 ( 3 ) :254 - 259. 被引量：1
2Piccart M J, Kerger J, Tomiak E, et al. Systemic treatment for locally advanced breast cancer:what we still need to learn after a decade of multimodality clinical trials [ J ]. Eur J Cancer, 1992,28 (2 - 3 ) : 667 - 672. 被引量：1
3Mauriac L, Durand M, Avril A, et al, Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre[J]. Ann Oncol, 1991, 2(5) :347 -354. 被引量：1
4Anderson ED, Forrest AP, Hawkins RA, et al. Primary systemic therapy for operable breast cancer [ J ]. Br J Cancer, 1991, 63 (4) : 561 -566. 被引量：1
5Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Instltute[J]. J Clin Oncol, 1998, 16( 1 ) : 93 - 100. 被引量：1
6Belembaogo E, Feillel V, Chollet P, et al. Neoadjuvant chemotherapy in 126 operable breast cancers[J]. Eur J Cancer, 1992, 28A(4 -5) : 896 -900. 被引量：1
7Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubitin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27[ J]. J Clin Oncol, 2003, 21 (22) :4165 -4174. 被引量：1
8Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel[ J ].J Clin Oncol, 2002, 20(6) : 1456 - 1466. 被引量：1
9Heller W, Mazhar D, Ward R, et al. Neoadjuvant 5-fluorouracil,epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer[ J]. Oncol Rep, 2007,17(1 ) :253 -259. 被引量：1
10Tfayli A, Holter J, Bova A, et al. Activity of combination chemotherapy, docetaxel and epirubicin as ncoadjuvant therapy for women with breast cancer[J]. Anticancer Res, 2006,26(6C) :4911 -4916. 被引量：1
6Rapoport B L,Demetriou G S,Moodley S D,et al.When and how do I use neoadjuvant chemotherapy for breast cancer[J].Curr Treat Options Oncol,2014,15(1):86. 被引量：1
7Redden M H,Fuhrman G M.Neoadjuvant chemotherapy in the treatment of breast cancer[J].Sutg Clin North Am,2013,93(2):493. 被引量：1
8Bear H D,Anderson S,Smith R E,et al.Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project B-27[J].J Clin Oncol,2006,24(13):2019. 被引量：1
9Melichar B,HornychováH,KalábováH,et al.Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma:a retrospective analysis[J].Med Oncol,2012,29(4):2577. 被引量：1
10Giacchetti S,Porcher R,Lehmann-Che J,et al.Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen[J].Br J Cancer,2014,110(6):1413. 被引量：1
